Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

Summary

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia

Timeline

Start

2023-02-15

Primary completion

2025-02-01

Completion

2025-05-15

Publications

• Xu Q, Guo Y, Gao M, Xue L, Xu H, Li H, Zhang X, Liu C, Li Y, Chen Q, Ren J, Sathiyanadan K, Hu Y, Tang L, Huang H, Wang X. IL-10-expressing, anti-CD19 CAR T cells for patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: an open-label, single-arm, phase 1 study. Lancet Haematol. 2025 Nov;12(11):e898-e907. doi: 10.1016/S2352-3026(25)00253-4. Epub 2025 Oct 16.

Drugs

Indications